Vera Therapeutics (VERA) News Today $41.27 -0.14 (-0.34%) (As of 12:04 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $63.50December 30 at 1:55 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and twDecember 27 at 2:19 AM | marketbeat.comGeode Capital Management LLC Buys 20,223 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 2.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,004,665 shares of the company's stock after acquiringDecember 24, 2024 | marketbeat.comPromising Developments in VYNE Therapeutics’ VYN202 Support Buy RatingDecember 23, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLCBarclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,395 shares of the company's stock after buying an additioDecember 23, 2024 | marketbeat.comVera Therapeutics: Strong Data In IgAN, But We May Be Too LateDecember 22, 2024 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.December 20, 2024 | marketbeat.comWellington Management Group LLP Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Wellington Management Group LLP lowered its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,071 shares of the compaDecember 20, 2024 | marketbeat.comState Street Corp Sells 331,746 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)State Street Corp decreased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 15.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,823,807 shares of the company's stock after selling 331,746 shares during the quarter. StateDecember 17, 2024 | marketbeat.comLord Abbett & CO. LLC Acquires 124,197 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Lord Abbett & CO. LLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 41.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 426,014 shares of the company's stock aDecember 16, 2024 | marketbeat.comMarshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total value of $821,450.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares in the company, valued at $4,034,117.48. This trade represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.December 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Has $1.37 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Y Intercept Hong Kong Ltd grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 283.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,911 shares of the company's stock after purchasing an aDecember 12, 2024 | marketbeat.comCarisma Therapeutics (CARM) Receives a Hold from Evercore ISIDecember 11, 2024 | markets.businessinsider.comVera Therapeutics (VERA) Receives a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 9, 2024 | globenewswire.comPier Capital LLC Invests $4.57 Million in Vera Therapeutics, Inc. (NASDAQ:VERA)Pier Capital LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 103,463 shares of the company's stock, valued at approximately $4December 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Point72 Asset Management L.P. lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 44.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 171,573 shares of the company's stock after purchDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $15.99 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Charles Schwab Investment Management Inc. lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 361,805 shares of the company's stock aDecember 8, 2024 | marketbeat.comVerition Fund Management LLC Invests $1.91 Million in Vera Therapeutics, Inc. (NASDAQ:VERA)Verition Fund Management LLC bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 43,210 shares of the company's stock, valued at aDecember 6, 2024 | marketbeat.comReadystate Asset Management LP Cuts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Readystate Asset Management LP lowered its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 93.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,683 shares of the company's stock after sellinDecember 5, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Fmr LLCFmr LLC lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,785,284 shares of the company's stock after selling 16,654 sharDecember 5, 2024 | marketbeat.comHighVista Strategies LLC Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)HighVista Strategies LLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 140.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 22,010 shares of the company's stock after buying an additional 12,848 shares during the period. HigDecember 3, 2024 | marketbeat.comCinctive Capital Management LP Purchases 13,728 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Cinctive Capital Management LP raised its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 39.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,500 shares of the companyDecember 3, 2024 | marketbeat.comIntech Investment Management LLC Purchases New Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Intech Investment Management LLC acquired a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 10,737 shares of the company's stock, valued at approximately $475,000. Other hedge fundsDecember 3, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned an average recommendation of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and twoDecember 2, 2024 | marketbeat.comJPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REGNovember 25, 2024 | msn.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 22, 2024 | globenewswire.comWells Fargo Initiates Coverage of Vera Therapeutics (VERA) with Overweight RecommendationNovember 22, 2024 | msn.comVera Therapeutics (VERA) Gets a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Now Covered by Wells Fargo & CompanyWells Fargo & Company began coverage on shares of Vera Therapeutics in a research note on Thursday. They set an "overweight" rating and a $70.00 price target on the stock.November 21, 2024 | marketbeat.comGSA Capital Partners LLP Trims Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)GSA Capital Partners LLP cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 62.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,113 shares of the company's stock after selling 20November 20, 2024 | marketbeat.comFirst Turn Management LLC Buys 113,550 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)First Turn Management LLC boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 53.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 326,494 shares of the company's stock after purchasing anNovember 19, 2024 | marketbeat.comVera Therapeutics appoints Jason Carter as Chief Legal OfficerNovember 18, 2024 | markets.businessinsider.comPolycythemia Vera Market Size in the 7MM is ~USD 1,800 million in 2023, estimated DelveInsightNovember 18, 2024 | theglobeandmail.comVera Therapeutics Appoints Jason S. Carter as Chief Legal OfficerNovember 18, 2024 | finance.yahoo.comVera Therapeutics (NASDAQ:VERA) Hits New 52-Week High - Time to Buy?Vera Therapeutics (NASDAQ:VERA) Hits New 52-Week High - Time to Buy?November 13, 2024 | marketbeat.comVera Therapeutics partners with University of Michigan on NEPTUNE match projectNovember 13, 2024 | markets.businessinsider.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.comVera Therapeutics Advances in Autoimmune TreatmentNovember 9, 2024 | markets.businessinsider.comVera Therapeutics to Participate at Upcoming Investor ConferencesNovember 8, 2024 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPSVera Therapeutics (NASDAQ:VERA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21).November 8, 2024 | marketbeat.comWedbush Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceWedbush increased their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research report on Friday.November 8, 2024 | marketbeat.comVera Therapeutics to Participate at Upcoming Investor ConferencesNovember 8, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comVera Therapeutics: Strong Buy Rating Backed by Financial Stability and Promising Atacicept DataNovember 7, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been given an average recommendation of "Buy" by the ten research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have aNovember 7, 2024 | marketbeat.comJ.P. Morgan Sticks to Its Buy Rating for Vera Therapeutics (VERA)November 6, 2024 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Given New $75.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday.November 5, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Up 7.3% - What's Next?Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.3% - Should You Buy?November 1, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Sells $720,450.00 in StockOctober 31, 2024 | insidertrades.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address “AI Killer” 10x More Powerful Than ChatGPT (Ad)Elon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI company behind it. Click here for the full scoop. VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼1.330.59▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼45▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vaxcyte News Today Qiagen News Today Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Nuvalent News Today Cytokinetics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s next tweet could help pay for your retirementElon Musk says the government is going bankrupt. Seniors are getting crushed by inflation.Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
